Protocol Ledger

NCT06652438 · Phase III · RECRUITING

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Interventional Phase III clinical trial protocol NCT06652438 sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-05 Enrollment: 448 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06652438
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)448 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06652438
Protocol FieldVerified Registry Value
NCT IdentifierNCT06652438
Consolidated Lead SponsorStichting Hemato-Oncologie voor Volwassenen Nederland
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment448 participants (ESTIMATED)
Registered Start Date2025-05-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI